The USPTO issues a notice of allowance to Galena BioPharma (GALE) of a patent covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu-expressing tumor having a fluorescence in situ hybridization ((FISH)) rating of less than ~2.0. The patent, once issued, will expire in 2028.
NeuVax is a peptide immunotherapy for the prevention of cancer recurrence. It is Galena's lead product. Currently, there are no approved HER2-directed therapies for patients with FISH ratings < 2.0.
GALE shares are up 11% premarket on higher volume.